NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: GUJTHEM · data 2026-10-31
Gujarat Themis Biosyn Ltd
In plain words
Price: 23.0% below its 52-week high of ₹471.8.
Delivery: 49.6% of traded shares were kept for delivery over the last 10 sessions, against 53.0% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹174 cr |
| Net profit (last 12 months) | ₹49 cr |
| Sales growth, 3 years (yearly) | 3.8% |
| Profit growth, 3 years (yearly) | -7.0% |
At a glance
Promoters 59.3% (-11.5 pts in a year), pledged 0.0%, institutions 16.4%.
P/E 81.3, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 17.4%, ROCE 18.2%, operating margin 38.9%: how much profit it earns on the money it uses.
Debt/equity 0.56, Profit growth -7.0% and sales growth 3.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Healthy operating margin (38.9%).
- Profit fell 7.0% a year over 3 years.
- Slow sales growth (3.8% a year over 3 years).
- Promoters cut their holding by 11.5 points in a year.
- Expensive on earnings (P/E 81.3).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 51.9% over the last 20 sessions vs 54.7% in the 40 before (0.95x); shares delivered per day 0.54x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹26.82 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Deal ● Insider
- 23 Sept 26Dividend Dividend ₹0.67 (ex-date) -0.3% next session
- 23 Sept 26Deal Bulk deal: L7 HITECH PRIVATE LIMITED sold ₹26.82 cr -0.3% next session
- 3 Sept 26Insider SAST disclosure: Pharmaceutical Business Group India… acquired shares -0.4% next session
- 4 Sept 25Dividend Dividend ₹0.67 (ex-date) -2.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 59.33% | 70.86% | 70.86% | 70.86% |
| Foreign institutions (FII) | 3.80% | 1.77% | 1.80% | 1.96% |
| Domestic institutions (DII) | 12.65% | 1.18% | 1.18% | 1.17% |
| Mutual funds | 9.63% | 1.16% | 1.16% | 1.16% |
| Retail investors | 13.15% | 15.18% | 15.55% | 15.76% |
| Number of shareholders | 28,781 | 27,010 | 26,886 | 27,325 |
Common questions
How much do promoters hold in Gujarat Themis Biosyn Ltd?
Promoters held 59.33% of Gujarat Themis Biosyn Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Gujarat Themis Biosyn Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.56.
What is Gujarat Themis Biosyn Ltd's P/E ratio?
About 81.3, based on the last 12 months' earnings and a price of ₹363.2 (data 2026-10-31).
What is the 52-week high and low of Gujarat Themis Biosyn Ltd?
The 52-week high is ₹471.8 and the 52-week low is ₹225.05.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Gujarat Themis Biosyn Ltd | ₹363.2 | ₹4,718 cr | 81.3 | — | 17.4% | 18.2% | 0.56 | -21.9% |
| Senores Pharmaceuticals Ltd. | ₹1,133.9 | ₹5,221 cr | 39.2 | 5.2 | 13.4% | 12.6% | 0.37 | +46.7% |
| Orchid Pharma Limited | ₹836.45 | ₹4,989 cr | 489.5 | — | 0.7% | 0.2% | 0.2 | +17.4% |
| SMS Pharmaceuticals Limited | ₹511.35 | ₹4,793 cr | 45.4 | — | 14.3% | 13.9% | 0.46 | +77.2% |
| RPG Life Sciences Limited | ₹2,575.7 | ₹4,255 cr | 35.6 | — | 20.3% | 21.3% | 0.03 | +5.3% |
| Evonile Pharma Limited | ₹1,692.4 | ₹4,182 cr | 42.7 | — | 11.6% | 11.8% | 0 | +144.9% |
Compare GUJTHEM with SENORES in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GUJTHEM in NSE Scanner →